Socioeconomics of obesity CV Anekwe, AR Jarrell, MJ Townsend, GI Gaudier, JM Hiserodt, ... Current obesity reports 9, 272-279, 2020 | 184 | 2020 |
Outcomes of COVID-19: disparities in obesity and by ethnicity/race MJ Townsend, TK Kyle, FC Stanford International Journal of Obesity 44 (9), 1807-1809, 2020 | 129 | 2020 |
COVID‐19 vaccination and obesity: optimism and challenges MJ Townsend, TK Kyle, FC Stanford Obesity 29 (4), 634-635, 2021 | 44 | 2021 |
Feeding intolerance in critically ill patients with COVID-19 R Liu, M Paz, L Siraj, T Boyd, S Salamone, TLV Lite, KM Leung, ... Clinical Nutrition 41 (12), 3069-3076, 2022 | 42 | 2022 |
Commentary: COVID-19 and obesity: exploring biologic vulnerabilities, structural disparities, and weight stigma MJ Townsend, TK Kyle, FC Stanford Metabolism-Clinical and Experimental 110, 2020 | 38 | 2020 |
Immune checkpoint inhibitor gastritis is often associated with concomitant enterocolitis, which impacts the clinical course A Haryal, MJ Townsend, V Baskaran, P Srivoleti, A Giobbie‐Hurder, ... Cancer 129 (3), 367-375, 2023 | 13 | 2023 |
Socioeconomics of Obesity. Curr Obes Rep. 2020; 9 (3): 272-9 CV Anekwe, AR Jarrell, MJ Townsend, GI Gaudier, JM Hiserodt, ... | 8 | 2023 |
Bamlanivimab efficacy in older and high-BMI outpatients with COVID-19 selected for treatment in a lottery-based allocation process EB Rubin, JA Boiarsky, LA Canha, A Giobbie-Hurder, M Liu, ... Open Forum Infectious Diseases 8 (12), ofab546, 2021 | 8 | 2021 |
Coverage of obesity and obesity disparities on American Board of Medical Specialties (ABMS) examinations S Yarlagadda, MJ Townsend, CJ Palad, FC Stanford Journal of the National Medical Association 113 (5), 486-492, 2021 | 8 | 2021 |
Obesity and eligibility for obesity treatments among adults with disabilities in the US MJ Townsend, MD Claridy, SS Bajaj, L Tu, FC Stanford American journal of preventive medicine 63 (4), 513-520, 2022 | 6 | 2022 |
Geography and equity: expanding access to obesity medicine diplomate care MJ Townsend, N Reddy, FC Stanford Int J Obes, 2022 | 4 | 2022 |
Pancreatitis and hyperlipasemia in the setting of immune checkpoint inhibitor therapy MJ Townsend, M Liu, A Giobbie-Hurder, JS Sack, NR LeBoeuf, FS Hodi, ... Journal of the National Comprehensive Cancer Network 21 (8), 831-840. e3, 2023 | 3 | 2023 |
Contemporary management of gastrointestinal, pancreatic and hepatic toxicities of immune checkpoint inhibitors MJ Townsend, IJ Benque, M Li, S Grover Alimentary Pharmacology & Therapeutics 59 (11), 1350-1365, 2024 | 2 | 2024 |
Prognostic value of inflammatory bowel disease-associated biomarkers in patients with immune checkpoint inhibitor Enterocolitis: a retrospective cohort study L Kogan, MJ Townsend, D Raj, AN Levy, A Giobbie-Hurder, S Grover Inflammatory Bowel Diseases 30 (6), 1032-1035, 2024 | 1 | 2024 |
Infliximab for steroid-refractory immune checkpoint inhibitor-induced acute pancreatitis MJ Townsend, FS Hodi, S Grover ACG Case Reports Journal 10 (3), e01018, 2023 | 1 | 2023 |
S65 distinct imaging patterns of immune checkpoint inhibitor-induced acute pancreatitis J Kondo, A Keraliya, MJ Townsend, A Giobbie-Hurder, ... Official journal of the American College of Gastroenterology| ACG 117 (10S …, 2022 | 1 | 2022 |
Su1275 IMMUNE CHECKPOINT INHIBITOR ESOPHAGITIS: TREATMENT OUTCOMES AND COMPLICATIONS A Mumtaz, MJ Townsend, JS Sack, S Grover Gastroenterology 166 (5), S-720-S-721, 2024 | | 2024 |
S1692 Trends and Disparities in Hepatology Televisits at a Large Tertiary Care Center MJ Townsend, JB Henson, K Wegermann, AJ Muir Official journal of the American College of Gastroenterology| ACG 118 (10S …, 2023 | | 2023 |
Sa1924 EXPANDED ELIGIBILITY FOR BARIATRIC PROCEDURES SHIFTS TOWARD PRIVATELY INSURED, MALE, AND HIGHER-INCOME PATIENTS WITH OBESITY MJ Townsend, MD Claridy, FC Stanford Gastroenterology 164 (6), S-482, 2023 | | 2023 |
Role of Reimbursement in the Delivery of Treatment for Obesity in Adults and Children CV Anekwe, VR Johnson, MJ Townsend, FC Stanford Handbook of Obesity-Volume 2, 88-96, 2023 | | 2023 |